Zydus Lifesciences has initiated Phase III clinical trials for its drug Desidustat to treat Sickle Cell Disease. The trial, involving 164 patients, is a collaboration with ICMR and builds on prior approvals for other indications.
Detailed Coverage
Zydus Lifesciences Starts Phase III Trial for Sickle Cell Disease Drug
Zydus Lifesciences will enroll 164 patients in a 203-day Phase III clinical trial for Sickle Cell Disease. Reader Takeaway: Pipeline advancement is positive; competitive landscape poses a watch point. ## What just happened Zydus Lifesciences has received approval to begin Phase III clinical trials for its drug Desidustat, targeting Sickle Cell Disease. This trial is a collaborative effort with the Indian Council of Medical Research (ICMR). ## Why this matters This development signifies a crucial step forward in Zydus' research and development pipeline. Desidustat, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), previously showed success in Phase II trials. The Phase III trial will evaluate its efficacy and safety in 164 sickle cell disease patients over 203 days, comparing it against a placebo in a double-blind, randomized, multicentre study. ## The backstory Desidustat is not a new drug for Zydus. It has already secured approval from the Drug Controller General of India (DCGI) in March 2022 for chronic kidney disease (CKD) anemia. It also received approval from China's National Medical Products Administration (NMPA) in March 2026 for renal anemia. Additionally, the US Food and Drug Administration (FDA) has granted Desidustat Orphan Drug Designation (ODD) for both Sickle Cell Disease and beta-thalassemia, potentially accelerating its path to market in the US. ## What changes now With the commencement of Phase III trials, Desidustat moves into the late-stage development phase for Sickle Cell Disease. This progression de-risks the asset and brings it closer to potential commercialization for this new indication. The collaboration with ICMR adds significant credibility and operational strength to the trial. ## Risks to watch A key watch point is the competitive landscape. Current standard treatments for sickle cell disease include hydroxyurea and blood transfusions. Desidustat will need to demonstrate superior efficacy and safety to capture market share. The 203-day trial duration also means investors will need to monitor future updates on trial milestones and data readouts. ## Peer comparison While direct peer comparisons for this specific trial initiation are not detailed in the filing, other pharmaceutical companies are also actively researching treatments for sickle cell disease, highlighting an area of significant unmet medical need and R&D focus within the sector. ## Context metrics (time-bound) The Phase III trial is planned to enroll 164 patients and will run for approximately 203 days. The well-tolerated dose identified in the Phase II study was 150 mg. ## What to track next Investors should closely monitor the progress of the Phase III clinical trial, including patient enrollment numbers, any interim data releases, and the final readout on efficacy and safety. Updates regarding regulatory submissions based on these trial results will be critical for future valuation.
